封面
市場調查報告書
商品編碼
1667942

子宮肌瘤治療市場 - 全球產業規模、佔有率、趨勢、機會和預測,按類型、按治療、按最終用戶、按地區和競爭進行細分,2020-2030 年預測

Uterine Fibroids Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Treatment, By End-User, By Region and Competition, 2020-2030F

出版日期: | 出版商: TechSci Research | 英文 186 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024 年全球子宮肌瘤治療市場價值為 47.4 億美元,預計到 2030 年將達到 77.6 億美元,預測期內的年複合成長率(CAGR) 為 8.53%。這種成長主要是由於育齡婦女子宮肌瘤盛行率不斷增加所致。子宮肌瘤是子宮內生長的非癌性腫瘤,影響全世界相當一部分女性,導致月經過多、骨盆腔疼痛和生殖併發症等症狀。人們對子宮肌瘤相關健康問題的認知不斷提高,鼓勵更多女性尋求醫療干預,從而增加了對有效治療方案的需求。製藥業的進步、微創手術的創新以及對非手術治療的日益成長的偏好正在重塑市場動態。此外,個人化醫療和標靶治療的轉變正在推動患者治療效果的改善。

市場概況
預測期 2026-2030
2024 年市場規模 47.4 億美元
2030 年市場規模 77.6 億美元
2025-2030 年複合年成長率 8.53%
成長最快的領域 子宮切除術
最大的市場 北美洲

主要市場促進因素

子宮肌瘤盛行率上升

主要市場挑戰

非手術治療選擇有限

目錄

第 1 章:產品概述

第 2 章:研究方法

第 3 章:執行摘要

第 4 章:顧客之聲

第5章:全球子宮肌瘤治療市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 依類型(漿膜下子宮肌瘤、壁內子宮肌瘤、黏膜下子宮肌瘤、帶蒂子宮肌瘤)
    • 依治療方法(荷爾蒙療法、雄性激素、促性腺激素釋放激素拮抗劑、子宮動脈栓塞術、肌瘤切除術、子宮切除術)
    • 按最終使用者(醫院和診所、門診手術中心、其他)
    • 按公司分類(2024)
    • 按地區
  • 市場地圖

第 6 章:北美子宮肌瘤治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 北美:國家分析
    • 墨西哥
    • 加拿大

第 7 章:歐洲子宮肌瘤治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 歐洲:國家分析
    • 德國
    • 英國
    • 義大利
    • 西班牙

第 8 章:亞太子宮肌瘤治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 亞太地區:國家分析
    • 印度
    • 韓國
    • 日本
    • 澳洲

第 9 章:南美子宮肌瘤治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 南美洲:國家分析
    • 阿根廷
    • 哥倫比亞

第 10 章:中東和非洲子宮肌瘤治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • MEA:國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 11 章:市場動態

  • 驅動程式
  • 挑戰

第 12 章:市場趨勢與發展

  • 合併與收購(如有)
  • 產品發布(如果有)
  • 最新動態

第 13 章:波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 顧客的力量
  • 替代產品的威脅

第 14 章:競爭格局

  • Gynesonics Inc.
  • Medtronic Plc.
  • Boston Scientific Corporation
  • Karl Storz Gmbh
  • Pfizer Inc.
  • Abbvie Inc.
  • Richard Wolf GmbH
  • CooperSurgical Inc.
  • Olympus Corporation
  • Myovant Sciences GmbH

第 15 章:策略建議

第16章 關於出版商,免責事項

簡介目錄
Product Code: 19021

The global uterine fibroids treatment market was valued at USD 4.74 billion in 2024 and is projected to reach USD 7.76 billion by 2030, growing at a compound annual growth rate (CAGR) of 8.53% during the forecast period. This growth is primarily driven by the increasing prevalence of uterine fibroids among women of reproductive age. Uterine fibroids, non-cancerous tumors that develop in the uterus, affect a significant proportion of women worldwide, leading to symptoms such as heavy menstrual bleeding, pelvic pain, and reproductive complications. Rising awareness of fibroid-related health issues is encouraging more women to seek medical interventions, thereby increasing the demand for effective treatment options. Advancements in pharmaceuticals, innovations in minimally invasive procedures, and a growing preference for non-surgical treatments are reshaping the market dynamics. Additionally, the shift toward personalized medicine and targeted therapies is driving improved patient outcomes.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 4.74 Billion
Market Size 2030USD 7.76 Billion
CAGR 2025-20308.53%
Fastest Growing SegmentHysterectomy
Largest MarketNorth America

Key Market Drivers

Rising Prevalence of Uterine Fibroids

The rising incidence of uterine fibroids is a key driver of market growth. Uterine fibroids, benign growths in the uterus, have become increasingly common, especially among women, impacting their quality of life and reproductive health. Factors such as delayed childbearing, changing lifestyles, and obesity are contributing to the rise in fibroid diagnoses. According to the Centers for Disease Control and Prevention (CDC) in 2021, 14.6% of women aged 18 and older in the United States have undergone a hysterectomy, a common surgical treatment for uterine fibroids. As more women experience symptoms such as heavy menstrual bleeding, pelvic pain, and fertility issues, the demand for medical interventions is increasing.

This growing patient population represents a substantial market opportunity for healthcare providers, pharmaceutical companies, and medical device manufacturers. In response, there has been a surge in research and development, leading to innovative treatments such as minimally invasive surgeries, pharmaceutical interventions, and novel therapies targeting the molecular mechanisms of fibroid growth.

Additionally, the rise in uterine fibroid awareness campaigns, improved access to healthcare, and enhanced patient education have made it easier for women to seek timely medical care, further driving the demand for uterine fibroid treatments. As the incidence of uterine fibroids continues to grow, there is a pressing need for innovative and patient-centric solutions.

Key Market Challenges

Limited Non-Surgical Treatment Options

A major challenge facing the global uterine fibroids treatment market is the limited availability of non-surgical alternatives. While surgical interventions have traditionally been the primary treatment option, non-surgical treatments are becoming increasingly important for women who wish to preserve fertility, reduce risks, and minimize recovery times.

Current pharmaceutical treatments, such as GnRH agonists and selective progesterone receptor modulators (SPRMs), help alleviate symptoms and reduce fibroid size. However, they often come with side effects, including hot flashes, bone density loss, and mood swings, and may not offer long-term solutions since fibroids tend to regrow after treatment discontinuation.

Minimally invasive non-surgical procedures like uterine artery embolization (UAE) and focused ultrasound surgery (FUS) have gained popularity. UAE blocks blood flow to the fibroids, causing them to shrink, while FUS uses high-intensity ultrasound waves to destroy them. Though these treatments are less invasive, they are not suitable for all patients. For example, UAE may not be ideal for women planning to conceive, and FUS has limitations regarding the size and location of fibroids it can treat. Moreover, access to these procedures can be limited by cost and availability, particularly in regions with constrained healthcare resources.

Key Market Players

  • Gynesonics Inc.
  • Medtronic Plc.
  • Boston Scientific Corporation
  • Karl Storz GmbH
  • Pfizer Inc.
  • Abbvie Inc.
  • Richard Wolf GmbH
  • CooperSurgical Inc.
  • Olympus Corporation
  • Myovant Sciences GmbH

Report Scope

The global uterine fibroids treatment market is segmented as follows:

By Type:

  • Subserosal Fibroids
  • Intramural Fibroids
  • Submucosal Fibroids
  • Pedunculated Fibroids

By Treatment:

  • Hormone Therapy
  • Androgens
  • Gonadotropin-Releasing Hormone Antagonists
  • Uterine Artery Embolization
  • Myomectomy
  • Hysterectomy

By End-User:

  • Hospitals & Clinics
  • Ambulatory Surgical Centers
  • Others

By Region:

  • North America (United States, Canada, Mexico)
  • Europe (France, United Kingdom, Italy, Germany, Spain)
  • Asia-Pacific (China, India, Japan, Australia, South Korea)
  • South America (Brazil, Argentina, Colombia)
  • Middle East & Africa (South Africa, Saudi Arabia, UAE)

Competitive Landscape

The report includes detailed company profiles of major players in the global uterine fibroids treatment market.

Available Customizations

TechSci Research offers the following customizations to the global uterine fibroids treatment market report:

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global Uterine Fibroids Treatment Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids, Pedunculated Fibroids)
    • 5.2.2. By Treatment (Hormone Therapy, Androgens, Gonadotropin-Releasing Hormone Antagonists, Uterine Artery Embolization, Myomectomy, Hysterectomy)
    • 5.2.3. By End-User (Hospitals & Clinics, Ambulatory Surgical Centers, Others)
    • 5.2.4. By Company (2024)
    • 5.2.5. By Region
  • 5.3. Market Map

6. North America Uterine Fibroids Treatment Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Treatment
    • 6.2.3. By End-User
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Uterine Fibroids Treatment Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Treatment
        • 6.3.1.2.3. By End-User
    • 6.3.2. Mexico Uterine Fibroids Treatment Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Treatment
        • 6.3.2.2.3. By End-User
    • 6.3.3. Canada Uterine Fibroids Treatment Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Treatment
        • 6.3.3.2.3. By End-User

7. Europe Uterine Fibroids Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Treatment
    • 7.2.3. By End-User
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Uterine Fibroids Treatment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Treatment
        • 7.3.1.2.3. By End-User
    • 7.3.2. Germany Uterine Fibroids Treatment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Treatment
        • 7.3.2.2.3. By End-User
    • 7.3.3. United Kingdom Uterine Fibroids Treatment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Treatment
        • 7.3.3.2.3. By End-User
    • 7.3.4. Italy Uterine Fibroids Treatment Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Treatment
        • 7.3.4.2.3. By End-User
    • 7.3.5. Spain Uterine Fibroids Treatment Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Treatment
        • 7.3.5.2.3. By End-User

8. Asia-Pacific Uterine Fibroids Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Treatment
    • 8.2.3. By End-User
    • 8.2.4. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Uterine Fibroids Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Treatment
        • 8.3.1.2.3. By End-User
    • 8.3.2. India Uterine Fibroids Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Treatment
        • 8.3.2.2.3. By End-User
    • 8.3.3. South Korea Uterine Fibroids Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Treatment
        • 8.3.3.2.3. By End-User
    • 8.3.4. Japan Uterine Fibroids Treatment Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Treatment
        • 8.3.4.2.3. By End-User
    • 8.3.5. Australia Uterine Fibroids Treatment Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Treatment
        • 8.3.5.2.3. By End-User

9. South America Uterine Fibroids Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Treatment
    • 9.2.3. By End-User
    • 9.2.4. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Uterine Fibroids Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Treatment
        • 9.3.1.2.3. By End-User
    • 9.3.2. Argentina Uterine Fibroids Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Treatment
        • 9.3.2.2.3. By End-User
    • 9.3.3. Colombia Uterine Fibroids Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Treatment
        • 9.3.3.2.3. By End-User

10. Middle East and Africa Uterine Fibroids Treatment Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Treatment
    • 10.2.3. By End-User
    • 10.2.4. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Uterine Fibroids Treatment Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Treatment
        • 10.3.1.2.3. By End-User
    • 10.3.2. Saudi Arabia Uterine Fibroids Treatment Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Treatment
        • 10.3.2.2.3. By End-User
    • 10.3.3. UAE Uterine Fibroids Treatment Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Treatment
        • 10.3.3.2.3. By End-User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Porters Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Products

14. Competitive Landscape

  • 14.1. Gynesonics Inc.
    • 14.1.1. Business Overview
    • 14.1.2. Company Snapshot
    • 14.1.3. Products & Services
    • 14.1.4. Financials (As Reported)
    • 14.1.5. Recent Developments
    • 14.1.6. Key Personnel Details
    • 14.1.7. SWOT Analysis
  • 14.2. Medtronic Plc.
  • 14.3. Boston Scientific Corporation
  • 14.4. Karl Storz Gmbh
  • 14.5. Pfizer Inc.
  • 14.6. Abbvie Inc.
  • 14.7. Richard Wolf GmbH
  • 14.8. CooperSurgical Inc.
  • 14.9. Olympus Corporation
  • 14.10. Myovant Sciences GmbH

15. Strategic Recommendations

16. About Us & Disclaimer